women on retatrutide and Weight Loss Research - GLP-1 Weight Loss & Peptide Support Using GLP-1 Medications Like Retatrutide
Description
The FDA approved an oral semaglutide tablet for weight loss in December 2025
Oral Semaglutide (Wegovy Pill) - FDA Approved December 2025: According to the OASIS 4 trial published in the New England Journal of Medicine, participants who took the Wegovy pill experienced 13.6% mean weight loss over approximately 64 weeks when including all participants regardless of adherence, compared to 2.2% for those taking placebo
This approach eliminates insurance hassles, pre-authorization delays, and hidden costs that often complicate traditional healthcare experiences
Alcohol acts as a diuretic, while semaglutide can cause fluid loss through its side effects
[DOI] [PMC free article] [PubMed] [Google Scholar] Underwood C
In many cases, those individuals are not authorized to practice medicine
